- Conditions
- Schizophrenia (Recent-onset)
- Interventions
- paliperidone palmitate, risperidone
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–39
of 39
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Alcoholism, Dual Diagnosis
- Interventions
- Risperidone + Desipramine
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Worcester, Massachusetts • Grand Rapids, Michigan • Lebanon, New Hampshire + 1 more
- Conditions
- Treatment-resistant Schizophrenia
- Interventions
- Clozapine, Antipsychotics,Other (non-Clozapine)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Schizophrenia
- Interventions
- ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 27
- States / cities
- Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole Lauroxil
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 14 more
- Conditions
- Schizophrenia
- Interventions
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid), PP1M 50 mg eq., PP1M 75 mg eq., PP1M 100 mg eq., PP1M 150 mg eq.
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Glendale, California • Long Beach, California + 21 more
- Conditions
- Schizophrenia, Bipolar Disorder
- Interventions
- Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users, Other Antipsychotics - New Starts
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 1,066 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 34
- States / cities
- Bullhead City, Arizona • Colton, California • Imperial, California + 31 more
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Diego, California
- Conditions
- Major Depressive Disorder, Suicidal Ideation
- Interventions
- paliperidone, lithium, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole Lauroxil, Paliperidone Palmitate
- Combination Product · Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 13 more
- Conditions
- Psychotic Disorders
- Interventions
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 8 Years to 19 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
- Conditions
- Schizophrenia
- Interventions
- PP6M, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 841 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 25
- States / cities
- Rogers, Arkansas • Anaheim, California • Costa Mesa, California + 21 more
- Conditions
- Schizophrenia
- Interventions
- Paliperidone
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Catonsville, Maryland
- Conditions
- Schizoaffective Disorder, Psychotic Disorder
- Interventions
- Placebo, Paliperidone ER
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 15
- States / cities
- Cerritos, California • Costa Mesa, California • Garden Grove, California + 12 more